Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768053 | 0.87 | KMT2A (0.57) | KDM4EALDH1A1KMT2AMEN1CCR3 | |
| SCHEMBL3773594 | 0.86 | CCR3 (0.52) | KDM4EALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL3770228 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1CCR3PARP1 | |
| SCHEMBL3767530 | 0.86 | ALDH1A1 (0.55) | KDM4EALDH1A1CCR3PARP1 | |
| SCHEMBL3772003 | 0.86 | CCR3 (0.55) | KDM4EALDH1A1KMT2AMEN1CCR3 | |
| SCHEMBL3767597 | 0.85 | HTR7 (0.52) | KDM4EALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL3767658 | 0.84 | MEN1 (0.47) | KDM4EALDH1A1KMT2AMEN1CCR3 | |
| SCHEMBL3766253 | 0.84 | KMT2A (0.55) | KDM4EALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL3773907 | 0.84 | KDM2B (0.53) | KDM4EALDH1A1KMT2AMEN1PARP1 | |
| SCHEMBL3799209 | 0.83 | NPC1 (0.52) | KDM4EALDH1A1KMT2AMEN1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | KDM4E 534/4885ALDH1A1 1210/4885MAPK1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.